RXII RXi Pharmaceuticals Corporation

0.65
0  0%
Previous Close 0.65
Open 0.65
Price To book 1.15
Market Cap 14.31M
Shares 22,045,000
Volume 241,024
Short Ratio 1.48
Av. Daily Volume 1,065,160

SEC filingsSee all SEC filings

  1. 8-K - Current report 17767350
  2. PRE 14A - Other preliminary proxy statements 17758652
  3. 8-K - Current report 17723746
  4. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17723735
  5. 8-K - Current report 17721633

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 final readout due 2H 2017.
RXI-109-1402
Connective tissue growth factor (CTGF)
Phase 2 first cohort data due 2Q 2017. Full data due 2H 2017.
Samcyprone - RXI-SCP-1502
Cutaneous warts
Phase 2 enrollment of first two cohorts has been completed. Third cohort ongoing.
RXI-109-1501
Retinal scarring
Phase 2 complete.
(RXI-109-1401)
Recurrence of keloids after keloid revision surgery
Phase 2 complete.
(RXI-109-1301)
Anti-scarring

Latest News

  1. RXi Pharmaceuticals to Present at 19th Annual TIDES: Oligonucleotide and Peptides Therapeutics Conference
  2. RXi Pharmaceuticals to Present an Update on its Consumer Product Development Programs at the Society for Investigative Dermatology 76th Annual Meeting
  3. RXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes
  4. The Life Sciences Report Examines RXi Pharmaceuticals Receiving Japanese Patent for RNAi Platform
  5. RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: 2016 By the Numbers : April 3, 2017
  6. RXi Pharmaceuticals to Present at the American Association for Cancer Research Annual Meeting
  7. RXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate Highlights
  8. RXi Pharma Derma Drug Secures Japanese Patent
  9. RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109
  10. RXi Pharmaceuticals to Present at the 5th Annual Cancer BioPartnering & Investment Forum
  11. RXi Pharmaceuticals to Present at the 2nd Annual Oligonucleotide and Peptide Therapeutics Conference
  12. RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2016 Financial Results on Thursday, March 30, 2017
  13. The Life Sciences Report Examines How the RXi-MirImmune Merger Is Aiming to Unlock Value Through Groundbreaking Technology
  14. Executives at Crane Manufacturer Buy Shares Amid Optimism about Infrastructure Spending Boost, Plus Other Insider Trading
  15. RXi Pharmaceuticals Appoints Medical Oncology Expert, Dr. James Griffin, to Scientific Advisory Board
  16. RXi Pharmaceuticals to Present at Leading Investor and Healthcare Conferences
  17. RXi Pharmaceuticals Appoints Leading Oncology Expert, Dr. Rolf Kiessling, to Scientific Advisory Board
  18. Retired CEO of NBT Bancorp Inc. (NBTB) Offloads Shares, Plus Other Exciting Insider Trading
  19. Mild Insider Selling at PriceSmart Inc. (PSMT) and ANSYS Inc. (ANSS); Insider Buying at Three Other Companies
  20. RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New Chief Business Officer